NCT01059812 - A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes | Biotech Hunter

Enrollment

424

Participants

Timeline

Start Date

February 1, 2010

Primary Completion Date

December 23, 2010

Study Completion Date

December 23, 2010

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

insulin degludec/insulin aspart

Injected subcutaneously twice daily. Dose was individually adjusted.

DRUG

biphasic insulin aspart 30

Injected subcutaneously twice daily. Dose was individually adjusted.

Trial Locations (46)

100

Novo Nordisk Investigational Site, Taipei

112

Novo Nordisk Investigational Site, Taipei

404

Novo Nordisk Investigational Site, Taichung

710

Novo Nordisk Investigational Site, Tainan City

833

Novo Nordisk Investigational Site, Kaohsiung City

10450

Novo Nordisk Investigational Site, Georgetown, Penang

16150

Novo Nordisk Investigational Site, Kota Bharu, Kelantan

16499

Novo Nordisk Investigational Site, Suwon

41200

Novo Nordisk Investigational Site, Klang, Selangor

56000

Novo Nordisk Investigational Site, Cheras

62250

Novo Nordisk Investigational Site, Putrajaya

70300

Novo Nordisk Investigational Site, Seremban

80100

Novo Nordisk Investigational Site, Johor Bahru

88586

Novo Nordisk Investigational Site, Kota Kinabalu

Unknown

Novo Nordisk Investigational Site, Shatin, New Territories

104 0061

Novo Nordisk Investigational Site, Chūōku

939 0363

Novo Nordisk Investigational Site, Imizu-shi

247 0056

Novo Nordisk Investigational Site, Kamakura-shi

582-0005

Novo Nordisk Investigational Site, Kashiwara-shi, Osaka

963-8851

Novo Nordisk Investigational Site, Koriyama-shi, Fukushima

862-0976

Novo Nordisk Investigational Site, Kumamoto-shi, Kumamoto

390 8510

Novo Nordisk Investigational Site, Matsumoto-shi

900 0032

Novo Nordisk Investigational Site, Naha

311-0113

Novo Nordisk Investigational Site, Naka-shi, Ibaraki

323-0022

Novo Nordisk Investigational Site, Oyama-shi, Tochigi

870 0039

Novo Nordisk Investigational Site, Ōita

060-0062

Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido

062-0007

Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido

569-1096

Novo Nordisk Investigational Site, Takatsuki-shi, Osaka

901 2104

Novo Nordisk Investigational Site, Urasoe-shi,

235-0045

Novo Nordisk Investigational Site, Yokohama-shi, Kanagawa

152-703

Novo Nordisk Investigational Site, Ansan

705-717

Novo Nordisk Investigational Site, Daegu

705-718

Novo Nordisk Investigational Site, Daegu

471-101

Novo Nordisk Investigational Site, Guri-si

480-717

Novo Nordisk Investigational Site, Gyeonggi-do

400-103

Novo Nordisk Investigational Site, Incheon

405-760

Novo Nordisk Investigational Site, Incheon

501-717

Novo Nordisk Investigational Site, Jeollanamdo

602-739

Novo Nordisk Investigational Site, Pusan

463-707

Novo Nordisk Investigational Site, Seongnam-si

02447

Novo Nordisk Investigational Site, Seoul

02841

Novo Nordisk Investigational Site, Seoul

120-752

Novo Nordisk Investigational Site, Seoul

134-701

Novo Nordisk Investigational Site, Seoul

220-701

Novo Nordisk Investigational Site, Wŏnju